Clinical trials: Adipocytic Sarcoma
Sarcoma, Soft Tissue
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy…
- Trial name
- NCT00297258
- Testing
- pazopanib
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 148 people
- Sponsor
- GlaxoSmithKline
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital
Retroperitoneal Sarcoma, Liposarcoma
A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
This phase I trial tests the safety, side effects, and best dose of abemaciclib and how well it works with radiation therapy before surgery in treating patients with high-risk adipocytic retroperitoneal sarcoma.
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT06025747
- Testing
- Abemaciclib, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Advanced Leiomyosarcoma, Adipocytic Sarcoma
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
- Conditions
- Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma
- Trial name
- NCT06957431
- Testing
- Zanzalintinib, Eribulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Advanced and/or Metastatic Sarcoma
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
The goal of this clinical research study is to learn if the combination of durvalumab and tremelimumab can help to control sarcoma. The safety of this drug combination will also be studied. This is an investigational study.
- Trial name
- NCT02815995
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Soft Tissue Sarcoma
Phase II Study of Regorafenib as Maintenance Therapy
Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib® to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6…
- Trial name
- EREMISS (NCT03793361)
- Testing
- Regorafenib
- Where
- 20 sites in France
- Volunteers
- 127 people
- Sponsor
- Centre Oscar Lambret
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
This multicenter study will enroll approximately 185 participants with metastatic or advanced sarcoma, to assess the effectiveness and safety of IMC-A12 monotherapy for this indication.
- Conditions
- Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma, Adipocytic Sarcoma
- Trial name
- NCT00668148
- Testing
- IMC-A12 (cixutumumab)
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 113 people
- Sponsor
- Eli Lilly and Company
Leiomyosarcoma, Liposarcoma
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell…
- Conditions
- Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult, Advanced Cancer
- Trial name
- LEADER (NCT03526679)
- Testing
- Eribulin, Lenvatinib
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital